Aredia, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Aredia is indicated for the treatment of patients with moderate to severe Paget's disease of bone. Aredia is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma.
Cautions:
Due to the risk of clinically significant deterioration in renal function, which may progress to renal failure, single doses of Aredia should not exceed 90 mg and the duration of infusion should be no less than 2 hours. Risk factors for the deterioration of renal function include elevated baseline creatinine and multiple cycles of bisphosphonate treatment.
Aredia IV (pamidronate disodium) 
